Drugmakers spent nearly $500 million on advertisements for obesity and diabetes treatments in the U.S. during the first seven months of this year, up 20% from the same period a year ago, according to new data released Friday.
The data, from advertising analytics firm MediaRadar, demonstrates the rush by companies to capture new customers after months of hype around Novo Nordisk 's diabetes drug Ozempic and weight loss counterpart Wegovy.
Those drugs and similar treatments have soared in demand this year for their ability to help patients lose unwanted pounds.
U.S. health-care providers wrote more than 9 million prescriptions for Ozempic, Wegovy, and other obesity and diabetes drugs during the last three months of 2022, up 300% from early 2020.
The top four drugs advertised were Novo Nordisk's Ozempic, Wegovy and diabetes pill Rybelsus and Boehringer Ingelheim's own diabetes treatment Jardiance, which is set to face drug price negotiations with the federal Medicare program.
Persons:
Doctor Thomas Horbach, Wegovy, Drugmakers, MediaRadar, Boehringer
Organizations:
Novo Nordisk, Novo Nordisk's Ozempic
Locations:
Germany, Munich, U.S